The Company said "FY23 guidance reflects its ability to earn substantial revenue from its commercial portfolio and partnered programs. It also reflects the Company’s commitment to investing in advancing its rich late-stage pipeline and preparing to commercialize its near-term commercial opportunities, eplontersen, olezarsen and donidalorsen, while maintaining a healthy balance sheet to continue investing for future growth." Sees FY23 operating expenses on a non-GAAP basis $970M-$995M; net operating loss on a non-GAAP basis $425M; Cash, cash equivalents and short-term investments $2.0B. "Our solid 2022 financial results reflected our ability to earn substantial revenues while investing in key programs with the potential to drive substantial future growth, including our near-term commercial opportunities," said Elizabeth L. Hougen, CFO of Ionis. "Additionally, we recently bolstered our balance sheet with more than $700M from our royalty monetization and sale and leaseback transactions. With approximately $2.5B in pro forma cash, we have the resources to continue to advance our innovative pipeline and achieve commercial readiness for eplontersen, olezarsen and donidalorsen."
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on IONS:
- Ionis reports fourth quarter and full year 2022 financial results
- Ionis Pharmaceuticals: GSK advances bepirovirsen into Phase 3 development
- Ionis Pharmaceuticals receives FDA Fast Track designation for olezarsen
- Ionis confirms FDA to hold advisory committee meeting on tofersen NDA
- Ionis Pharmaceuticals price target raised to $62 from $60 at Piper Sandler